ACTU
Actuate Therapeutics Inc.

117
Loading...
Loading...
News
all
press releases
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
MTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest
Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 529,786...
MarketBeat·24d ago
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Actuate Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·26d ago
News Placeholder
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Here's What Happened
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Time to Buy...
MarketBeat·1mo ago
News Placeholder
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU
Voss Capital LP grew its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 101.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 286,140...
MarketBeat·2mo ago
News Placeholder
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago
News Placeholder
BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU
BIOS Capital Management LP raised its stake in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·3mo ago
News Placeholder
What is HC Wainwright's Estimate for ACTU FY2025 Earnings?
Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Actuate Therapeutics in a research report issued on Wednesday...
MarketBeat·3mo ago
News Placeholder
HC Wainwright Has Negative Forecast for ACTU FY2029 Earnings
Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - HC Wainwright reduced their FY2029 EPS estimates for shares of Actuate Therapeutics in a note issued to investors on Wednesday, November 19th...
MarketBeat·3mo ago
<
1
2
...
>

Latest ACTU News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.